New obesity drug delivery methods tested in Early-Stage trial

NCT ID NCT07226778

Ongoing Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Nov 10, 2025 · Last updated May 15, 2026 · Updated 21 times

Summary

This early-stage study tests how the body processes two different injection forms of maridebart cafraglutide, an experimental drug for overweight or obesity. About 348 adults aged 18-60 with a BMI between 25 and 40 will receive a single dose and be monitored for drug levels and side effects. The goal is to compare the two delivery methods, not to treat the condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Anaheim Clinical Trials

Anaheim, California, 92801-2658, United States
Fortrea Clinical Research Unit - Dallas

Dallas, Texas, 75247-4989, United States
Fortrea Clinical Research Unit - Daytona Beach

Daytona Beach, Florida, 32117-5116, United States
Fortrea Clinical Research Unit Inc. - Madison

Madison, Wisconsin, 53704-2526, United States

Conditions

Explore the condition pages connected to this study.

OBESITY OVERWEIGHT